Clinical Trial

A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multi-center , open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of HYP-6589 in monotherapy in advanced solid tumors and combination with tyrosine kinase inhibitors in patients with advanced NSCLC with target-driven gene positivity.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-26; most recent amendment 2025-12-21.
Status change: Not Yet Recruiting → Recruiting 2024-12-03
Trial Details
NCT Number NCT06712680
Lead Sponsor Sichuan Huiyu Pharmaceutical Co., Ltd
Conditions Solid Tumor
Enrollment 115 participants
Start Date 2024-11-27
Primary Completion 2028-04-10 (estimated)
Study Completion 2028-04-10 (estimated)
Updated on ClinicalTrials.gov 2025-12-23